ADVANCING POLYCYSTIC KIDNEY DISEASE (PKD) TREATMENT: EXPLORING EMERGING THERAPIES AND BREAKTHROUGHS

Prajwal Rana*, Yashsavi Bali, Jyoti Gupta, Raman Gupta and Shallu Dhiman

ABSTRACT

The most common sign of Autosomal dominant polycystic kidney disease (ADPKD) is the development of
multiple kidney cysts over time, which eventuall y lead to end stage kidney disease (ESKD) and require renal
replacement therapy. To treat ADPKD, several treatments have been developed. However, not all these remedies
have been effective in preventing the development of the disease. It is essential to ha ve a thorough knowledge of
the mechanisms leading to cyst formation and growth before diving into specific therapy for controlling ADPKD.
Numerous clinical trials are undergoing over the past two decades aiming to treat ADPKD as a result of significant
res earch efforts. Tolvaptan is the only pharmaceutical agent found to be successful in delaying the deterioration of
kidney function in ADPKD, even though Tolvaptan has several undesirable side effects, including thirst, polyuria,
and liver damage when used f or an extended period. In this review, we have covered the detailed pathophysiology
and molecular mechanisms of PKD, as well as the possibility of emerging therapies in the clinical development of
PKD.

Keywords: Autosomal dominant polycystic kidney diseas e, End stage kidney disease, Emerging therapies.